Lycia Therapeutics grants Henderson 20,000 stock options

The two awards have different exercise prices and service-based vesting schedules, with one award vesting in full on October 22, 2027.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. director Jane Henderson was granted stock options covering 57,666 common shares on August 11, 2026, with a $3.70 exercise price. They vest as to 1/48 of the award monthly over four years, with the first tranche vested August 6, 2026, subject to her service on each vesting date. On October 22, 2026, she was granted options covering 20,000 common shares at an $18 exercise price; 100% vest October 22, 2027, subject to her service on that date.

Insider Trade Summary

Grant/Award: 77,666 shares

Grant/Award 2 txns

Insider Henderson Jane

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F3	20,000	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) F1, F2	57,666	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 77,666 contracts (Direct)

Footnotes (3)

1. F1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
2. F2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on August 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
3. F3. The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

Key Figures

Options covering common shares: 57,666 shares Exercise price: $3.70 per share Vesting schedule: 1/48 of the award monthly over four years +3 more

6 metrics

Options covering common shares 57,666 shares Award dated August 11, 2026

Exercise price $3.70 per share Options awarded August 11, 2026

Vesting schedule 1/48 of the award monthly over four years Options awarded August 11, 2026

Options covering common shares 20,000 shares Award dated October 22, 2026

Exercise price $18 per share Options awarded October 22, 2026

Vesting 100% on October 22, 2027 Options awarded October 22, 2026, subject to service on the vesting date

Key Terms

vesting, tranche, Rule 16a-2(a)

3 terms

vesting technical

"vest as to 1/48 of the total award monthly over four years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

tranche technical

"first tranche vested on August 6, 2026"

A tranche is one slice of a larger financing or investment that is released, sold, or paid out in separate parts rather than all at once. Investors care because each slice can carry different risk, return and timing—like buying pieces of a cake where some slices are richer or come later—so the specific tranche you hold affects when you get paid and how much you might gain or lose.

Rule 16a-2(a) regulatory

"reported herein pursuant to Rule 16a-2(a)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LYCA options did director Jane Henderson receive?

Jane Henderson received options covering 57,666 common shares on August 11, 2026, and options covering 20,000 common shares on October 22, 2026.

When do Jane Henderson's LYCA options expire?

The options covering 57,666 common shares expire on August 10, 2036. The options covering 20,000 common shares expire on October 21, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:21 PM EDT Accepted by SEC EDGAR 10/26/2026 - 07:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Henderson Jane

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7	08/11/2026(1)		A		57,666		(2)	08/10/2036	Common Stock	57,666	$0	57,666	D
Stock Option (Right to Buy)	$18	10/22/2026		A		20,000		(3)	10/21/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on August 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

3. The options will vest as to 100% of the award on October 22, 2027, subject to the Reporting Person's provision of service to the Issuer on such vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)